Immunotherapy

Prostate Cancer

The prostate is a walnut-sized gland located below the bladder, in front of the rectum and at the base of the bladder and the penis. It is found only in males and makes the seminal fluid, which is the liquid in semen that carries and protects the sperm. Prostate cancer begins when healthy cells in prostate tissue mutate and begin to grow uncontrollably. They become cancerous cells that accumulate and form a mass known as a primary tumor. Prostate cancer often grows very slowly, usually causing no to few symptoms in its early stages.

Treatment options for prostate cancer include surgery, radiation therapy, hormone therapy, chemotherapy and immunotherapy. The first immunotherapy approved by the U.S. Food and Drug Administration (FDA) for metastatic castration-resistant prostate cancer is a personalized cancer vaccine, meaning that the treatment is custom-made to fight against your own cancer cells. This strategy involves collecting your own white blood cells, modifying them in a lab with a vaccine to recognize the prostate cancer cells and then injecting the white blood cells and vaccine back into your body. Your cells are then able to find and destroy the cancer.

Clinical trials are a valuable treatment option to consider. Many of the advances in cancer treatment are helping save lives today because of the research conducted through clinical trials. By participating in a trial, you may have access to cutting-edge treatments that are not yet widely available (see Clinical Trials). Ask your doctor if a trial might be right for you.

 

FDA-Approved Immunotherapies for Prostate Cancer
As of 10/20/2017
sipuleucel-T (Provenge)

 

Additional Resources

 

Previous Next


Register Now! Sign Up For Our Free E-Newletter!

Read Inspiring Cancer Survivor Stories

Order Your Guides Here